CTNM Valuation

Contineum Therapeutics Inc

Add to Watchlist

Advanced Chart

10.650

-0.36(-3.270%)1D

CTNM Relative Valuation

CTNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CTNM is overvalued; if below, it's undervalued.

Historical Valuation

Contineum Therapeutics Inc (CTNM) is now in the Undervalued zone, suggesting that its current forward PS ratio of 11.01 is considered Undervalued compared with the five-year average of -6.72. The fair price of Contineum Therapeutics Inc (CTNM) is between 20.46 to 70.14 according to relative valuation methord. Compared to the current price of 11.01 USD , Contineum Therapeutics Inc is Undervalued By 46.18%.

Relative Value

Fair Zone

20.46-70.14

Current Price：11.01

46.18%

Undervalued

-5.03

Trailing

Forward

-1.33

EV/EBITDA

Contineum Therapeutics Inc. (CTNM) has a current EV/EBITDA of -1.33. The 5-year average EV/EBITDA is -4.03. The thresholds are as follows: Strongly Undervalued below -13.59, Undervalued between -13.59 and -8.81, Fairly Valued between 0.75 and -8.81, Overvalued between 0.75 and 5.53, and Strongly Overvalued above 5.53. The current Forward EV/EBITDA of -1.33 falls within the Historic Trend Line -Fairly Valued range.

-1.56

EV/EBIT

Contineum Therapeutics Inc. (CTNM) has a current EV/EBIT of -1.56. The 5-year average EV/EBIT is -4.27. The thresholds are as follows: Strongly Undervalued below -14.28, Undervalued between -14.28 and -9.27, Fairly Valued between 0.74 and -9.27, Overvalued between 0.74 and 5.75, and Strongly Overvalued above 5.75. The current Forward EV/EBIT of -1.56 falls within the Historic Trend Line -Fairly Valued range.

10.65

Contineum Therapeutics Inc. (CTNM) has a current PS of 10.65. The 5-year average PS is 53.87. The thresholds are as follows: Strongly Undervalued below -8.30, Undervalued between -8.30 and 22.79, Fairly Valued between 84.96 and 22.79, Overvalued between 84.96 and 116.05, and Strongly Overvalued above 116.05. The current Forward PS of 10.65 falls within the Undervalued range.

-4.70

P/OCF

Contineum Therapeutics Inc. (CTNM) has a current P/OCF of -4.70. The 5-year average P/OCF is -8.01. The thresholds are as follows: Strongly Undervalued below -17.88, Undervalued between -17.88 and -12.95, Fairly Valued between -3.07 and -12.95, Overvalued between -3.07 and 1.86, and Strongly Overvalued above 1.86. The current Forward P/OCF of -4.70 falls within the Historic Trend Line -Fairly Valued range.

-4.24

P/FCF

Contineum Therapeutics Inc. (CTNM) has a current P/FCF of -4.24. The 5-year average P/FCF is -7.43. The thresholds are as follows: Strongly Undervalued below -16.22, Undervalued between -16.22 and -11.82, Fairly Valued between -3.03 and -11.82, Overvalued between -3.03 and 1.36, and Strongly Overvalued above 1.36. The current Forward P/FCF of -4.24 falls within the Historic Trend Line -Fairly Valued range.

Contineum Therapeutics Inc (CTNM) has a current Price-to-Book (P/B) ratio of 1.78. Compared to its 3-year average P/B ratio of 1.17 , the current P/B ratio is approximately 51.79% higher. Relative to its 5-year average P/B ratio of 1.17, the current P/B ratio is about 51.79% higher. Contineum Therapeutics Inc (CTNM) has a Forward Free Cash Flow (FCF) yield of approximately -17.11%. Compared to its 3-year average FCF yield of -13.46%, the current FCF yield is approximately 27.14% lower. Relative to its 5-year average FCF yield of -13.46% , the current FCF yield is about 27.14% lower.

1.72

P/B

Median3y

1.17

Median5y

1.17

0.00

FCF Yield

Median3y

-13.46

Median5y

-13.46

Competitors Valuation Multiple

The average P/S ratio for CTNM's competitors is 8.96, providing a benchmark for relative valuation. Contineum Therapeutics Inc Corp (CTNM) exhibits a P/S ratio of 10.65, which is 18.91% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

CTNM.O

Contineum Therapeutics Inc

Lyell Immunopharma Inc

Performance Decomposition

Market capitalization of CTNM increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of CTNM in the past 1 year is driven by Unknown.